Highest-materiality recent filing
Dogwood Q2 net loss $11.5M; Halneuron Phase 2b on track, 217 patients enrolled
Net loss $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025; includes $6.7M non-cash IPR&D impairment.
Dogwood Therapeutics shareholders approve increase in authorized shares at annual meeting
Stockholders approved amendment to Certificate of Incorporation to increase authorized shares of common and preferred stock with 28,431,012 for, 243,744 against.
Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026
Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.
Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed
145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.
Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026
Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).
Dogwood Therapeutics shareholders approve warrant exercise for up to 4.4M shares
Proposal to approve potential exercise of warrant for 4,386,037 shares passed with 29,286,786 votes for, 19,057 against, 4,466 abstentions.
Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones
Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.
Dogwood Therapeutics raises $12.5M upfront; potential $14.4M from warrant exercise
Gross proceeds of $12.5M from registered direct offering and concurrent private placement; potential additional $14.4M upon warrant exercise.
Dogwood Therapeutics enters ATM equity distribution agreement to sell up to $8.6M of common stock
Agreement with Northland Securities to sell up to $8,558,712 of common stock via at-the-market offerings.
Stockholders approved the potential issuance of common stock upon conversion of Series A, A-1, and A-2 preferred stock.
Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026
Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.
Dogwood Therapeutics posts Q4 2025 update presentation; no specific data in excerpt
Presentation filed as Exhibit 99.1 highlights first-in-class therapies for cancer neuropathy.
Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b
Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).
Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025
Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.
Dogwood Therapeutics increases CFO Angela Walsh's base salary to $321,903
Board approved CFO salary increase from $279,916 to $321,903 per year.
Shareholders approve 108,612-share increase to Dogwood equity incentive plan at annual meeting
Plan amendment raises shares reserved from 82,500 to 191,112; approved with 275,020 for, 6,482 against, 1,284 abstain.
Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway
Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.
Regained compliance with Nasdaq minimum stockholders' equity requirement ($2.5M).
Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).
Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026
Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.
Dogwood converts $19.9M debt and interest to Series A-1 preferred equity
$19.5M principal plus accrued interest ($19,926,891 total) exchanged for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.
Pharmagesic financials: $4.9M loss, $82M deficit; Dogwood provides $19.5M funding
Pharmagesic (Holdings) Inc. (acquired Oct 7) had $4.9M net loss in 2023; no revenue; R&D costs $3.9M.
Dogwood Therapeutics receives Nasdaq delisting notice for low stockholders' equity
Stockholders' equity fell below $2.5M minimum per Q3 2024 10-Q; delisting risk under Nasdaq Rule 5550(b)(1).
Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche
Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.
Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov
Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.
Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.
Virios Q2 net loss $1.0M; Long-COVID Phase 2a data expected Oct 2024
Net loss $1.0M ($0.05/sh) vs $1.4M ($0.08/sh) in Q2 2023; revenue was $0.
Virios Therapeutics annual meeting elects all six director nominees, ratifies FORVIS as auditor
Quorum of 8,699,494 shares (45.17% of voting power) present at June 18, 2024 meeting.
Virios Therapeutics granted Nasdaq exception until Oct 28, 2024 to regain $1.00 bid price compliance
Nasdaq Hearing Panel grants exception until October 28, 2024 to meet minimum $1.00 bid price rule.
Priced public offering of 8,500,000 shares at $0.20 per share for gross proceeds of approx. $1.7M.
Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%
Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.
Second Nasdaq letter received May 1, 2024 for failure to maintain $1.00 minimum bid price.
Virios shareholders approve reverse stock split at special meeting
Special meeting held March 1, 2024; quorum 64.58% of shares outstanding.
Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2
Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.
Virios Therapeutics cuts cash compensation 10%; grants stock options to officers and directors
Board approved 10% salary reduction for all employees including executive officers, effective March 1, 2024.
Virios Therapeutics: FDA alignment on Phase 3 fibromyalgia and Phase 2 Long-COVID endpoint clarity
FDA agreed on Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia treatment.
Virios Q3 net loss narrows to $1.2M; secures FDA guidance for IMC-1 Phase 3
Net loss $1.2M ($0.06/share) vs $2.6M ($0.28/share) in Q3 2022; cash $4.8M.
Virios Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period
Received Nasdaq notice on Nov 2, 2023; bid price closed below $1.00 for 30 consecutive business days.
FDA guidance received for IMC-1 Phase 3 fibromyalgia trial; multiple life science companies reviewing Phase 2 data for partnership.
Virios Therapeutics terminates at-the-market sales agreement with JonesTrading
Sales agreement terminated effective Sept 28, 2023; no sales since Aug 9, 2023; up to $6.7M capacity.
Virios Q2 net loss $1.4M ($0.08/share); cash $4.6M; FDA IMC-1 toxicology adequate; pK study planned
Net loss $1.4M ($0.08 per share) vs $3.7M ($0.44) in Q2 2022; R&D down to $0.6M, G&A down to $0.9M.
FDA deems IMC-1 chronic toxicology program adequate; Virios plans Phase 3 start mid-2024
FDA communicated that IMC-1 chronic toxicology studies appear adequate to support safety at proposed dose for chronic use.
Virios announces positive Long-COVID data for valacyclovir/celecoxib; cash $4.5M
Female long-COVID patients showed significant improvements in fatigue, pain, and autonomic dysfunction after 14 weeks of Val/Cel vs routine care.
Virios Therapeutics enters $6.7M at-the-market equity offering with JonesTrading
Agreement allows sale of up to $6.7M of common stock via ATM offering under Rule 415.
Virios shareholders reject proposed reverse stock split at annual meeting
Reverse stock split proposal (1:2 to 1:25) failed: 9,011,430 for, 720,787 against, 123,006 abstain.
Virios Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq letter on May 24, 2023 confirming compliance with Listing Rule 5550(a)(2).
Virios Therapeutics reports Q1 2023 net loss of $1.5M; FDA amenable to IMC-1 Phase 3 proposal
Net loss $1.5M ($0.08 per share) vs $4.0M ($0.48) in Q1 2022; R&D expenses fell to $0.5M from $2.8M.
Virios Therapeutics gets Nasdaq bid-price extension to Oct 30, 2023
Received extension letter on May 2, 2023; new compliance period ends Oct 30, 2023.
Virios reports constructive FDA meeting for IMC-1 fibromyalgia; Long-COVID data expected June 2023
End-of-Phase 2 FDA meeting for IMC-1 was constructive; Company seeks guidance to advance to Phase 3.
Virios posts FY2022 net loss $12.2M; cash $7.0M; FDA meeting on IMC-1 Phase 3 in March
Net loss Q4 2022 $2.0M ($0.11/share) vs $4.5M in Q4 2021; FY2022 net loss $12.2M ($1.11) vs $16.0M in FY2021.
promoted Angela Walsh from her prior role of Senior Vice President of Finance to the Company’s Chief Financial Officer, effective immediately upon the Closing on October 7, 2024
accepted the resignation of Richard Burch from the Board, effective as of immediately prior to the Closing on October 7, 2024
and Melvin Toh as a director of the Company
appointed Alan Yu as a director of the Company
Max materiality 0.85 · Median 0.60 · Most common event other_material